An economic model based on the ECHELON-2 trial demonstrated cost-effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma (PTCL).
Anuraag Kansal, PhD
Advertisement
Articles by Anuraag Kansal, PhD
Advertisement
Latest Updated Articles
- Cost-effectiveness of Brentuximab Vedotin With Chemotherapy in Treatment of CD30-Expressing PTCL
Published: February 11th 2020 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis
2
New Insight on Biologic Initiation Patterns for Treating Severe Asthma
3
Nerandomilast a "No-Brainer" for First-Line Pulmonary Fibrosis Therapy: Justin M. Oldham, MD, PhD, MS
4
Predicting Patient Response in the Move Toward Precision Medicine in Myasthenia Gravis
5
